Cutera (NASDAQ:CUTR) Research Coverage Started at StockNews.com

StockNews.com initiated coverage on shares of Cutera (NASDAQ:CUTR) in a research report released on Wednesday morning. The brokerage issued a sell rating on the medical device company’s stock.

CUTR has been the subject of a number of other reports. Piper Sandler reaffirmed a “neutral” rating and set a $1.00 price target (down from $3.00) on shares of Cutera in a research report on Friday, August 9th. Stephens decreased their price target on shares of Cutera from $10.00 to $5.00 and set an “overweight” rating for the company in a research report on Friday, August 9th.

Cutera Trading Down 1.5 %

Shares of Cutera stock opened at $0.39 on Wednesday. The company has a fifty day moving average price of $0.55 and a 200 day moving average price of $1.04. Cutera has a twelve month low of $0.28 and a twelve month high of $4.97. The stock has a market cap of $7.87 million, a price-to-earnings ratio of -0.06 and a beta of 1.26.

Hedge Funds Weigh In On Cutera

Institutional investors and hedge funds have recently added to or reduced their stakes in the company. Ground Swell Capital LLC purchased a new position in Cutera in the 2nd quarter valued at about $37,000. Squarepoint Ops LLC boosted its position in Cutera by 164.5% in the 2nd quarter. Squarepoint Ops LLC now owns 113,964 shares of the medical device company’s stock valued at $172,000 after buying an additional 70,870 shares during the last quarter. Finally, Bank of Montreal Can boosted its position in Cutera by 14.2% in the 2nd quarter. Bank of Montreal Can now owns 282,704 shares of the medical device company’s stock valued at $455,000 after buying an additional 35,248 shares during the last quarter. 90.70% of the stock is owned by hedge funds and other institutional investors.

About Cutera

Cutera, Inc provides aesthetic and dermatology solutions for medical practitioners worldwide. It develops, manufactures, and markets energy-based product platforms for medical practitioners; and distributes third-party manufactured skincare products. The company provides AviClear for the treatment of mild, moderate, and severe inflammatory acne vulgaris; Secret PRO, a device that utilizes fractional CO2 for skin resurfacing and radio frequency (RF) microneedling for skin revitalization; truFlex, a bio-electrical muscle stimulation device designs to strengthen, firm and tone the abdomen, buttocks, and thighs; and excel V/V+, a vascular and benign pigmented lesion treatment platform.